
Roche and Dyno advance AAV gene therapies for neurological diseases
Dyno Therapeutics and Roche have announced a second research collaboration to develop adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. Dyno and Roche previously agreed a research collaboration and license agreement for neurological diseases and liver-directed therapies in October 2020. Under the terms of this new collaboration, Dyno… Read More
